Search | Clinical Trials Finder

Conditions: Ulcerative Colitis (UC)
Interventions: Upadacitinib (ABT-494), Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 147
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more

Conditions: Crohn's Disease (CD)
Interventions: ABT-494; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 27
States / cities: La Jolla, California • San Francisco, California • Gainesville, Florida + 22 more

Conditions: Spondyloarthritis
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 41
States / cities: Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 103
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more

Conditions: Psoriatic Arthritis
Interventions: Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more

Conditions: Crohn's Disease
Interventions: Vedolizumab, Upadacitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Colorado Springs, Colorado + 12 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib (ABT-494); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Huntington Beach, California • Los Angeles, California • Coral Gables, Florida + 12 more

Conditions: Psoriasis, Atopic Dermatitis
Interventions: In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast; Device · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Crohn's Disease
Interventions: Upadacitinib, Placebo for Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 119
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 93 more

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13); Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 52
States / cities: Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more

Conditions: Hidradenitis Suppurativa
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 33
States / cities: Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more

Conditions: Rheumatoid Arthritis
Interventions: targeted synthetic DMARD class, non-TNFi-biologic class; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 924 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 48
States / cities: Auburn, Alabama • Birmingham, Alabama • Peoria, Arizona + 41 more

Conditions: Atopic Dermatitis
Interventions: Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 76
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 63 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: Upadacitinib, Tocilizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 8 more

Conditions: Rheumatoid Arthritis
Interventions: Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 52
States / cities: Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 69 more

Conditions: Ankylosing Spondylitis (AS)
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Phoenix, Arizona • Beverly Hills, California • Covina, California + 18 more

Conditions: Atopic Dermatitis
Interventions: Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more

Conditions: Ulcerative Colitis Acute
Interventions: Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Psoriatic Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 72
States / cities: Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 65 more

Conditions: Crohn's Disease
Interventions: Upadacitinib, Placebo for Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 123
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 30
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 26 more

Conditions: EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Interventions: Upadacitinib 30mg Dose, Upadacitinib Matching Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Search by objective public record fields.

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

RA-PRO PRAGMATIC TRIAL

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis